19 Jul

Girona Regional Council supports GoodGut innovation

Girona Regional Council supports GoodGut innovation


GoodGut is one of 14 companies that have been selected under the Girona Regional Council business support program, which will create some 40 jobs throughout the province this year.

“We want to encourage the hiring of new personnel and drive actions to improve issues associated with innovation and technology within companies,” highlighted Josep Antoni Frias, regional councillor for Economic Promotion and DIPLAB in the Girona Regional Council. Frias met with representatives of the companies receiving this support on 28 July. CEO Mariona Serra attended on behalf of GoodGut.

The Regional Council valued the cutting-edge research being carried out at Goodgut in the field of digestive diseases, as well as the team’s history. This biotechnology firm was created in 2014 by Dr. Xavier Aldeguer, head of Digestive Medicine at Hospital Josep Trueta; Dr. Jesús García-Gil, Microbiology Chair; and Mariona Serra, PhD in pharmacology.  Afterwards, the team was joined by Jaume Amat as a strategic consultant through the Bioemprèn programme (he is also on the CataloniaBio Board of Directors). Goodgut currently has a team of five working at its facilities in the University of Girona Science and Technology Park – Girona Emprèn.

Photo: Martí Artalejo

12 Jul

GoodGut gets Retos grant for non-invasive test for early detection of colon cancer

GoodGut gets Retos grant for non-invasive test for early detection of colon cancer


Ministry of the Economy and Competitiveness has given GoodGut €1.1 million under the Research Challenges (Retos) programme to validate and develop a non-invasive system for colorectal cancer screening based on bacterial markers in faeces. The project is called Risk Assessment Intestinal Disease for Colorectal Cancer (RAID-CRC) and will last three years.

The innovation of this new test lies in its ability to detect precancerous lesions in patients from a stool sample even before they experience symptoms. This will “reduce the number of false positives you get with the faecal occult blood test, decrease the need for colonoscopies and help prevent colorectal cancer,” explains Dr Mariona Serra, co-founder and CEO of GoodGut. RAID-CRC will be implemented to screen people with mid-to-high risk, meaning individuals over 50.

The test is currently undergoing clinical validation, which will finish over the coming months, at the Digestive System Unit at Dr. Josep Trueta University Hospital, led by Dr. Xavier Aldeguer; the Digestive System Unit at Bellvitge University Hospital, led by Dr. Jordi Guardiola; and the Genetic Counselling Unit at the Catalan Institute of Oncology, led by Dr. Gabriel Capellà and Dr. Joan Brunet.

Close collaboration between public institutions and companies is key to the development of medical devices like RAID-CRC. “The ‘Retos’ programme makes this interdisciplinary action possible, ensuring the success of the project,” says Mariona Serra.